Genscript Biotech (OTCMKTS:GNNSF) Shares Down 8.5% – Time to Sell?

Shares of Genscript Biotech Co. (OTCMKTS:GNNSF) fell 8.5% on Tuesday . The company traded as low as C$1.30 and last traded at C$1.30. 4,000 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 6,892 shares. The stock had previously closed at C$1.42.

Genscript Biotech Trading Down 8.5%

The business has a 50-day simple moving average of C$1.64 and a 200-day simple moving average of C$1.95.

Genscript Biotech Company Profile

GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.

The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.